Optimi Health signs psilocybin supply agreement with

VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company producing natural, scalable and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc. (“Halucenex”), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on the research of novel psychedelic compounds, the development and licensing of psychedelic compounds for the pharmaceutical and nutraceutical markets, and the production of clinical trials on the medical benefits of psychedelic medicine.

Additionally, Optimi would like to confirm that the supply agreement covers the entire first batch of psilocybe cubensis mushrooms recently harvested by the company from its facility in Princeton, BC. Mushrooms will be delivered to Halucenex as whole, dried fruiting bodies of mushrooms.

“This first supply agreement, which comes so soon after our first full cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP-compliant psilocybin,” said Bill Ciprick, CEO of ‘Optimized. “From this initial batch of proof of concept, our culture team will continue to scale our operations to meet industry demands, nationally and internationally with licensed entities and for individual patients in Canada, in accordance with Special Access Program Terms. ”

Halucenex CEO Bill Fleming says the deal with Optimi is one that both companies will benefit from.

“We are very pleased to move forward on this supply agreement with the Optimi Health team,” said Fleming. “One of our top priorities in developing a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to ensure a safe and consistent supply of GMP psilocybin.”

Authorized parties interested in purchasing Optimi Psilocybin and Functional Mushroom products should email [email protected] where a member of the sales team will respond within 24 hours.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (ENG: 8BN)

Optimi Health Inc. is a Canadian success story producing and supplying EU-GMP grade natural psilocybin and functional mushrooms focusing on the health and wellness markets. Built with the goal of producing natural and scalable mushroom formulations for transformational human experiences, the company’s goal is to be the premier trusted and compassionate provider of natural and safe GMP grade psilocybin across the globe. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities totaling 20,000 square feet in Princeton, in British Columbia.

In order to fully investigate the science of mushrooms, the company has received a research exemption under the Food and Drug Regulations (FDR) from Health Canada for the use of psilocybin and psilocin for scientific purposes through its wholly-owned subsidiary Optimi Labs Inc. Optimi has also obtained a distributor’s license under the Narcotic Control Regulations of Canada governing the possession, distribution, sale, laboratory analysis, and research and development of psilocybin formulations and psilocin. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and regulations to ensure safe and superior Canadian mushroom production.

Optimi was recently granted an amendment to its dealer license by Health Canada, allowing the company to possess a quota of up to 5000 kg of dried psilocybin mushrooms – the equivalent of 10 kg of psilocybin – and 100 g of psilocin.

ABOUT HALUCENEX

Halucenex operates a 6,000 square foot medical facility in Windsor, Nova Scotia with six treatment rooms and a secure laboratory dedicated to psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process – mycological research, extraction technology and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs.

Clinically, Halucenex is focused on researching psilocybin, psilocybin derivatives, and other psychedelic drugs to treat clients with PTSD and anxiety using its comprehensive psilocybin-assisted psychotherapy treatment model. . Halucenex is committed to advancing the science around the use of psilocybin in psychedelic-assisted psychotherapy by:

For more information or to request an interview, please contact:

Michael Kydd
Media and Stakeholder Relations Advisor
Email: [email protected]
Telephone: +1 (902) 880 6121

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. Any statement that expresses or implies discussions of expectations, beliefs, plans, goals, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as ” will likely result”, “are expected”, “expects”, “will continue”, “is planned”, “anticipates”, “believes”, “estimates”, “intends”, “plans”, “plans”, “projection”, “strategy”, “target” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results will differ materially from those expressed in such forward-looking statements. No assurance can be given that such expectations will prove to be correct and undue reliance should not be placed on the forward-looking statements included in this press release. Such statements are only made as as of the date of this press release. In particular, and without limitation, this press release contains forward-looking statements relating to proposed activities to be conducted under the Company’s reseller license and associated activities relating to Psilocybin and Psilocin and plans , orientations and objectives of Optimi.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially. of those disclosed or implied by such statements. forward-looking statements. These risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under the headings “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form. Company dated January 12, 2022. , and other continuous disclosure documents available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors appear from time to time, and it is not possible for Optimi to predict them all or assess the impact of each of these factors or the extent to which any one factor, or combination of factors, may cause results significantly different from those contained. in any forward-looking statements.

All forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Photos accompanying this ad are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b1df7352-0b4b-48e9-a3f1-950de89cd66a

https://www.globenewswire.com/NewsRoom/AttachmentNg/82589a86-5ae3-4399-b33e-5b4b9927bcb4

About Hector Hedgepeth

Check Also

Experts explain the ‘perfect storm’ of endemic RSV and influenza

The headlines of the past few weeks are sounding the alarm about earlier and more …